Latest Press Releases
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
Company appoints Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer With decades of proven experience, they bring leadership to successfully lead...
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline
- Co-led by new investors Foresite Capital and TCGX - - Proceeds to advance late-stage clinical programs in bladder cancer towards FDA approval - August 2, 2023, 8:00 AM Eastern Standard Time IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. today announced the close...
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC
IRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc., announced today completion of patient enrollment for BOND-003, a single arm, Phase 3, monotherapy study evaluating cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer (NMIBC)...
Upcoming Conferences
LUGPA 2023 Annual Meeting
Nov 2 – 4, Booth 106
Orlando
contact: information@cgoncology.com
24th Annual Meeting of the SUO
2023 Annual Meeting
Nov 28 – Dec 1, 2023
Washington DC
contact: information@cgoncology.com
CG in the News
Targeted Oncology
July 25, 2023
BOND-003 Study of Cretostimogene Grenadenorepvec in NMIBC Completes Enrollment
ENDPOINTS NEWS
May 24, 2023
Endpoints 20 under 40 – Arthur Kuan is featured
ONCOLOGY TUBE
May 23, 2023
Pembrolizumab combined with CG0070. How can this help patients with NMIBC? Roger Li
